Sino Biopharmaceutical Sustainability Profile
Sino Biopharmaceutical Limited, commonly referred to as Sino Biopharm, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Founded in 1997, the company has established a strong presence across major operational regions, including Mainland China and various international markets. Sino Biopharm focuses on the research, development, manufacturing, and marketing of innovative medicines, particularly in the fields of oncology, cardiovascular diseases, and infectious diseases. With a robust portfolio of core products, Sino Biopharm distinguishes itself through its commitment to high-quality standards and advanced biopharmaceutical technologies. The company has achieved significant milestones, including numerous product approvals and a growing market share, positioning itself as a key contributor to the healthcare landscape. Notably, Sino Biopharm's dedication to innovation and patient-centric solutions has earned it recognition as a trusted name in the biopharmaceutical sector.
DitchCarbon Score
How does Sino Biopharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sino Biopharmaceutical's score of 39 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sino Biopharmaceutical's reported carbon emissions
In 2024, Sino Biopharmaceutical, headquartered in Hong Kong, reported total greenhouse gas emissions of approximately 20,822,010 kg CO2e from Scope 1 and 189,981,390 kg CO2e from Scope 2, resulting in a combined total of about 208,220,010 kg CO2e. This marks a slight increase from 2023, where emissions were approximately 23,923,961 kg CO2e, comprising 17,046,220 kg CO2e from Scope 1 and 222,193,400 kg CO2e from Scope 2. The company has set a target to reduce greenhouse gas emissions intensity by 20% per RMB 1 million of revenue by 2025, using 2021 as the baseline year. This commitment reflects Sino Biopharmaceutical's proactive approach to managing its carbon footprint and aligns with industry standards for climate action. Sino Biopharmaceutical has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. The emissions data is sourced directly from Sino Biopharmaceutical Limited, with no cascaded data from parent or related organizations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 21,711,730 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 253,214,050 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Sino Biopharmaceutical's Industry?
How Carbon Intensive is Sino Biopharmaceutical's Location?
Sino Biopharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sino Biopharmaceutical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
